AU2002215345A1 - Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer - Google Patents

Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Info

Publication number
AU2002215345A1
AU2002215345A1 AU2002215345A AU1534502A AU2002215345A1 AU 2002215345 A1 AU2002215345 A1 AU 2002215345A1 AU 2002215345 A AU2002215345 A AU 2002215345A AU 1534502 A AU1534502 A AU 1534502A AU 2002215345 A1 AU2002215345 A1 AU 2002215345A1
Authority
AU
Australia
Prior art keywords
methods
prostate cancer
modulators
diagnosis
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002215345A
Inventor
Daniel Afar
Kurt C. Gish
Peter Hevezi
David H. Mack
Keith E. Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EOS Biotechnology Inc
Original Assignee
EOS Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/847,046 external-priority patent/US20020068036A1/en
Application filed by EOS Biotechnology Inc filed Critical EOS Biotechnology Inc
Publication of AU2002215345A1 publication Critical patent/AU2002215345A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002215345A 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer Abandoned AU2002215345A1 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US68757600A 2000-10-13 2000-10-13
US09/687,576 2000-10-13
US73374200A 2000-12-08 2000-12-08
US73328800A 2000-12-08 2000-12-08
US09/733,742 2000-12-08
US09/733,288 2000-12-08
US26395701P 2001-01-24 2001-01-24
US60/263,957 2001-01-24
US27679101P 2001-03-16 2001-03-16
US27688801P 2001-03-16 2001-03-16
US60/276,791 2001-03-16
US60/276,888 2001-03-16
US28192201P 2001-04-06 2001-04-06
US60/281,922 2001-04-06
US28621401P 2001-04-24 2001-04-24
US60/286,214 2001-04-24
US09/847,046 2001-04-30
US09/847,046 US20020068036A1 (en) 2000-10-13 2001-04-30 Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
US28858901P 2001-05-04 2001-05-04
US60/288,589 2001-05-04
PCT/US2001/032045 WO2002030268A2 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Publications (1)

Publication Number Publication Date
AU2002215345A1 true AU2002215345A1 (en) 2002-04-22

Family

ID=27581207

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002215345A Abandoned AU2002215345A1 (en) 2000-10-13 2001-10-12 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer

Country Status (6)

Country Link
EP (1) EP1474528A4 (en)
JP (1) JP2005506033A (en)
AU (1) AU2002215345A1 (en)
CA (1) CA2425569A1 (en)
MX (1) MXPA03003151A (en)
WO (1) WO2002030268A2 (en)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2286304C (en) 1997-04-10 2007-08-07 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
JP4855577B2 (en) 1998-06-01 2012-01-18 アジェンシス，インコーポレイテッド Novel serpentine transmembrane antigen expressed in human cancer and use thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ES2260059T3 (en) 1999-09-29 2006-11-01 Diagnocure Inc. RNA MESSENGER OF PCA3 IN BENIGN AND MALIGNED PROSTATE FABRICS.
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
EP1366158B1 (en) * 2000-07-28 2008-05-21 Ulrich Wissenbach Trp8 markers for cancer
CA2432639A1 (en) 2000-11-16 2002-05-23 Cemines, Llc Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
AU2002249816A1 (en) * 2000-12-15 2002-07-24 Millennium Pharmaceuticals, Inc. Human sugar transporter proteins, potassium channel proteins, phospholipid transporter proteins and methods of use thereof
AU2002246708A1 (en) 2000-12-15 2002-08-12 Agensys, Inc. Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
US7081516B2 (en) 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
CA2439702A1 (en) * 2001-03-05 2002-09-19 Aventis Pharma S.A. Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
WO2003000113A2 (en) 2001-06-20 2003-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050272120A1 (en) 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1499350A4 (en) * 2001-08-31 2006-02-08 Agensys Inc Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2532757T3 (en) 2001-09-06 2015-03-31 Agensys, Inc. Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer
AU2002367585A1 (en) * 2001-09-17 2003-09-22 Millennium Pharmaceuticals, Inc. Methods of using 46828, a human acyl-coa synthetase
US20030100034A1 (en) * 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
CA2470088A1 (en) * 2001-12-20 2003-07-03 Tularik Inc. Identification of an amplified gene and target for drug intervention
AU2003217421A1 (en) * 2002-02-19 2003-09-09 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
WO2005067629A2 (en) * 2004-01-06 2005-07-28 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
US20040162236A1 (en) * 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
AU2003231196C1 (en) * 2002-05-10 2009-05-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated PMEPA1 and cancer
DE10234901A1 (en) * 2002-07-26 2004-02-12 Metagen Pharmaceuticals Gmbh New nucleic acids encoding Mrp4, useful in the diagnosis of prostatic, bladder and ovarian tumors, also in screening for specific binding agents, and potential therapeutic agents
US7408048B2 (en) 2002-08-09 2008-08-05 Melbourne Health Mammalian grainyhead transcription factors
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
EP1575993A4 (en) * 2002-08-26 2007-07-25 Univ Case Western Reserve Methods for treating patients and identifying therapeutics
EP1573331A1 (en) * 2002-12-09 2005-09-14 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with phosphodiesterase 9a1 (pde9a1)
WO2004070056A2 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
JP2004357702A (en) * 2003-05-09 2004-12-24 Research Association For Biotechnology New protein and dna encoding the same
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
SG10201701737XA (en) 2003-11-06 2017-04-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005083086A2 (en) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
US8008442B2 (en) 2004-04-22 2011-08-30 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2005106488A2 (en) * 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2)
BRPI0510883B8 (en) 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
EP1794314A2 (en) * 2004-07-23 2007-06-13 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
ES2579805T3 (en) 2004-09-23 2016-08-16 Genentech, Inc. Antibodies and conjugates engineered with cysteine
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
WO2006074914A2 (en) * 2005-01-13 2006-07-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Human rna helicase and therapeutic uses thereof
ES2364670T3 (en) * 2005-02-25 2011-09-12 Oncotherapy Science, Inc. PEPTIDE VACCINES FOR LUNG CANCERS EXPRESSING TTK POLYPEPTIDES.
HUE034263T2 (en) 2006-10-27 2018-02-28 Genentech Inc Antibodies and immunoconjugates and uses therefor
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2583377T3 (en) * 2007-06-08 2016-09-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2009032292A1 (en) * 2007-09-06 2009-03-12 Case Western Reserve University Methods for diagnosing and treating cancers
PT3106873T (en) * 2007-10-25 2019-10-18 Toray Industries Method for detection of cancer
JP5589274B2 (en) * 2007-10-25 2014-09-17 東レ株式会社 Immune inducer
AU2014240339B2 (en) * 2007-10-25 2017-07-13 Toray Industries, Inc. Method for detection of cancer
CA2727915C (en) 2008-07-15 2016-04-26 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
TWI580431B (en) 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Hig2 and urlc10 epitope peptide and vaccines containing the same
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
US20110256157A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
BR112012028010A2 (en) * 2010-05-03 2017-09-26 Genentech Inc isolated antibody, cell, isolated nucleic acid, method of identifying a first antibody that binds to a tat425 antigenic epitope attached to an antibody, methods of inhibiting cell growth, therapeutic treatment of determining the presence of a tat425 protein and diagnosing the presence of a tumor in a mammal
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
MX2013013054A (en) 2011-05-12 2014-02-20 Genentech Inc Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides.
SI2750713T1 (en) 2011-10-14 2016-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
ES2660029T3 (en) 2012-10-12 2018-03-20 Medimmune Limited Antibody-pyrrolobenzodiazepine conjugates
CN105102068B (en) 2012-10-12 2018-06-01 Adc疗法责任有限公司 Pyrrolobenzodiazepines Zhuo-antibody conjugates
CN104837502B (en) 2012-10-12 2018-08-10 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
MX364326B (en) 2012-10-12 2019-04-23 Medimmune Ltd Pyrrolobenzodiazepine - anti-psma antibody conjugates.
WO2014057122A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
ES2658888T5 (en) 2012-12-21 2021-10-19 Medimmune Ltd Pyrrolobenzodiazepines and their conjugates
CN105246894A (en) 2012-12-21 2016-01-13 斯皮罗根有限公司 Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
JP6444902B2 (en) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepine and its conjugates
CA2901941C (en) 2013-03-13 2020-04-07 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9649390B2 (en) 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR20150132500A (en) * 2013-03-15 2015-11-25 메타마크 제네틱스, 인크. Compositions and methods for cancer prognosis
SG11201601005XA (en) 2013-08-12 2016-03-30 Genentech Inc 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP3082874A2 (en) 2013-12-16 2016-10-26 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013861A2 (en) 2013-12-16 2017-10-10 Genentech Inc drug and antibody conjugates, compounds, treatment method and pharmaceutical composition
CA2929565A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US20150252425A1 (en) * 2014-03-05 2015-09-10 Caldera Health Ltd. Gene expression profiling for the diagnosis of prostate cancer
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN107108724A (en) 2014-09-12 2017-08-29 豪夫迈·罗氏有限公司 Cysteine engineered antibody and conjugate
BR112017005393A2 (en) 2014-09-17 2017-12-05 Genentech Inc compound of formula I, method of preparing a conjugate of formula a, conjugate of formula a1, composition comprising a mixture of antibody-drug conjugate compounds, pharmaceutical composition, and use of a conjugate or composition
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
JP6752204B2 (en) 2014-12-03 2020-09-09 ジェネンテック， インコーポレイテッド Quadruple amine compounds and their antibodies-drug conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3433621A1 (en) 2016-03-25 2019-01-30 H. Hoffnabb-La Roche Ag Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
JP7093767B2 (en) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepine prodrug and its antibody conjugate
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
RS61795B1 (en) 2017-02-08 2021-06-30 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CA3055132A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1
JP2020517609A (en) 2017-04-18 2020-06-18 メディミューン リミテッド Pyrrolobenzodiazepine complex
BR112019021880A2 (en) 2017-04-20 2020-06-02 Adc Therapeutics Sa COMBINATION THERAPY WITH ANTI-AXL-DRUG ANTIBODY CONJUGATE
WO2018229222A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
WO2019034764A1 (en) 2017-08-18 2019-02-21 Medimmune Limited Pyrrolobenzodiazepine conjugates
CA3074688A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2020010305A1 (en) * 2018-07-05 2020-01-09 The Board Of Regents Of The University Of Oklahoma Gene signatures for cancer characterization and methods of use
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CA3115110A1 (en) 2018-10-24 2020-04-30 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028498A1 (en) * 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Method for molecular staging of prostate cancer
US5858673A (en) * 1996-06-24 1999-01-12 Charlotte-Mecklenburg Hospital Authority Method for detecting prostate cells
WO1999037811A1 (en) * 1998-01-21 1999-07-29 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
CA2321119A1 (en) * 1998-02-23 1999-08-26 Dana-Farber Cancer Institute, Inc. Method for identifying mismatch repair glycosylase reactive sites, compound and uses thereof
US6476207B1 (en) * 1998-06-11 2002-11-05 Chiron Corporation Genes and gene expression products that are differentially regulated in prostate cancer
CA2392428A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences Inc. Nucleic acids, proteins, and antibodies
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer

Also Published As

Publication number Publication date
JP2005506033A (en) 2005-03-03
EP1474528A2 (en) 2004-11-10
EP1474528A4 (en) 2006-06-14
MXPA03003151A (en) 2003-08-19
WO2002030268A2 (en) 2002-04-18
WO2002030268A3 (en) 2004-08-26
CA2425569A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
AU2002215345A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
AU2002330039A1 (en) Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2002068677A8 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002257004A1 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU3752700A (en) Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators
AU2001290902A1 (en) Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3755300A (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002239431A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002357734A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2001249317A1 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
AU2001249493A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001283463A1 (en) Methods of diagnosis of cancer and screening for cancer modulators